Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onglyza to be used as an adjunct to diet and exercise to improve blood sugar control
Subscribe to our email newsletter
AstraZeneca and Bristol-Myers Squibb have reported that FDA has approved Onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults.
Onglyza is indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults with type 2 diabetes mellitus.
Onglyza once daily can be used in combination with commonly prescribed oral anti-diabetic medications – such as metformin, sulfonylureas (SUs) or thiazolidinediones (TZDs) – or as a monotherapy to reduce glycosylated hemoglobin (A1C) levels. The dose of Onglyza is 2.5mg or 5mg once daily, regardless of meals, said the company.
David Brennan, CEO of AstraZeneca, said: “With the FDA approval of Onglyza, physicians and adult patients with type 2 diabetes have an important new treatment to help improve glycemic control.
“Onglyza is the product of a major collaboration between AstraZeneca and Bristol-Myers Squibb to further the understanding of how best to treat this challenging disease and help adult patients achieve their treatment goals,” he added.